Phase IIb Trials

News Phase IIb Trials

• Data from historic phase IIb clinical trial for tuberculosis vaccine candidate MVA85A

  Data from a Phase IIb clinical trial evaluating the safety and efficacy of MVA85A in preventing tuberculosis (TB) in infants. MVA85A is a TB vaccine candidate designed to boost immune responses already primed by the Bacille Calmette-Guérin (BCG) vaccine, the currently licensed and widely used TB vac more

• Anergis obtains U.S. patent for AllerT

  Anergis has been granted patent protection for its AllerT birch pollen allergy treatment in the U.S. The patent No. 8,343,503 granted by the U.S. Patent Office broadly covers composition of matter and medical use of AllerT, the lead product of Anergis. AllerT is composed of a set of three contiguous more

• ThromboGenics and BioInvent Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402

  ThromboGenics NV and co-development partner BioInvent International announced the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban (Xarelto®; Bayer), an oral anticoagulant.  The study showed that the incidence of venous thromboembolism (VTE) was simil more

Publications Phase IIb Trials

• Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial

  by Lynn T. Matthews, Sengeziwe Sibeko, Leila E. Mansoor, Nonhlanhla Yende-Zuma, David R. Bangsberg, Quarraisha Abdool Karim Background Antiretroviral prophylaxis may be a critical strategy to reduce periconception HIV transmission. Maximizing the benefit of periconception pharmacologic HIV risk-r more

• Model-Based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

  A model-based strategy was used to inform the early clinical development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor under development for the treatment of hyperlipidemia. The objectives of this model-based approach were to enable bridging variable pharmacokinetic effects, d more

Market studies Phase IIb Trials

• Rare and Niche Diseases Catalyst Monitor - Key Event Analysis H1 2012

  Introduction GlobalData’s new report, "Rare and Niche Diseases Catalyst Monitor - Key Event Analysis H1 2012" takes a look at rare and niche diseases, which are an area of intense interest in the global biopharmaceutical industry today. The passage of the Orphan Drug Act in the United States in 19 more

• Sophiris Bio, Inc. (SHS) - Financial and Strategic SWOT Analysis Review

  Sophiris Bio, Inc. (SHS) - Financial and Strategic SWOT Analysis Review Summary Sophiris Bio, Inc. (Sophiris), formerly Protox Therapeutics Inc., is a biopharmaceutical company. It focuses on the research, development and commercialization of products for the treatment of urological diseases, such more

Websites Phase IIb Trials